{"groups":[{"description":"Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).\n\nMK-3475: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.\n\nPomalidomide: Pomalidomide is given at standard dose of 4 mg daily orally for 21 days\n\nDexamethasone: Dexamethasone is given at 40 mg orally weekly","id":"FG000","title":"Pomalidomide, Dexamethasone & MK-3475"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were recruited from the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center between December 2014 and May 2016."}